Guardant, Nuvalent link diagnostics to targeted cancer pipeline

Guardant Health and Nuvalent have entered a multi-year strategic collaboration to develop companion diagnostics for Nuvalent’s targeted cancer pipeline, using Guardant’s Infinity platform and an initial emphasis on Guardant360 Tissue. Under the deal, Guardant’s tissue and liquid biopsy tests will be used in certain Nuvalent global clinical studies, the companies will evaluate assays that could support future regulatory approvals, and they may work together on commercialization if Nuvalent’s products are approved. The announcement comes as Nuvalent advances late-stage programs in ALK-positive and ROS1-positive non-small cell lung cancer, including an NDA submission for neladalkib in April 2026 and an FDA review for zidesamtinib with a September 18, 2026, PDUFA date. (investors.guardanthealth.com)

Why it matters: While this is a human oncology deal rather than a veterinary one, it’s another signal that biomarker-led drug development and companion diagnostics are becoming more tightly linked across oncology. For veterinary professionals watching the diagnostics market, the partnership underscores how tissue and liquid biopsy platforms are increasingly being positioned not just as testing tools, but as part of the regulatory and commercialization strategy around targeted therapies. It also adds to a pattern for Guardant, which recently highlighted similar pharma collaborations as part of its broader oncology growth story. (fiercebiotech.com)

What to watch: The next milestones are likely to be Nuvalent’s regulatory updates, including the September 18, 2026, FDA action date for zidesamtinib and any future disclosure about which specific Nuvalent programs will get companion diagnostic support under the Guardant deal. (investors.nuvalent.com)